Research To Practice | Oncology Videos

Latest Episodes:

Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer Sep 25, 2024

Show notes

Featuring an interview with Dr Tiffany A Traina, including the following topics:

Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34)
Activity and tolerability of enfortumab vedotin for mTNBC (21:47)
Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13)
Selection and sequencing of therapeutic options for advanced breast cancer (26:36)
Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00)
Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32)
Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40)
Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16)

CME information and select publications

Biliary Tract Cancers | Striving for Consensus: Optimizing the Current and Future Management of Biliary Tract Cancers Sep 20, 2024

Show notes

Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics:

Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00)
Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27)
Case: A woman in her early 70s with recurrent gallbladder cancer with biliary obstruction (15:56)
Targeting FGFR and IDH Alterations for Advanced BTCs — Dr Goyal (35:00)
Case: A woman in her late 30s with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (ICC) (54:25)
Case: A man in his late 60s with cholangiocarcinoma metastases to liver and bone (1:01:33)
Case: A woman in her 60s with ICC with an IDH1 mutation (1:10:05)
Emerging Role of HER2-Targeted Therapy for Advanced BTCs — Dr Harding (1:21:15)
Case: A man in his early 40s with cholangiocarcinoma metastatic to the appendix (1:57:25)
New Directions in the Management of BTCs — Dr Javle (2:01:09)

CME information and select publications

Neuroendocrine Tumors | Pamela Kunz, MD Sep 19, 2024

Show notes

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 2: Later-Line Treatment for Advanced NETs — Pamela Kunz, MD

CME information and select publications

Neuroendocrine Tumors | Simron Singh, MD, MPH Sep 19, 2024

Show notes

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 1: First-Line Therapy for Advanced Neuroendocrine Tumors (NETs) — Simron Singh, MD, MPH

CME information and select publications

Neuroendocrine Tumors | Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors Sep 19, 2024

Show notes

Featuring perspectives from Dr Pamela Kunz and Dr Simron Singh, including the following topics:

Introduction (0:00)
Overview (4:04)
Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors (NETs) (27:07)
Multitarget Tyrosine Kinase Inhibitors for the Treatment of NETs (39:37)
Other New Advances in the Management of NETs (50:29)

CME information and select publications

Gastrointestinal Cancers | John Strickler, MD Sep 13, 2024

Show notes

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 1: HER2-Targeted Strategies for HER2-Positive Gastroesophageal and Colorectal Cancers — John Strickler, MD

CME information and select publications

Gastrointestinal Cancers | Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers Sep 13, 2024

Show notes

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr John Strickler, including the following topics:

Introduction: Back-to-School Special (0:00)
Biomarker Assays in Advanced Gastrointestinal (GI) Cancers (10:12)
Sequencing of Treatment for HER2-Positive GI Cancers (28:37)
Toxicities Associated with Anti-HER2 Treatment (48:32)
Novel Agents and Strategies for HER2-Positive GI Cancers (58:10)

CME information and select publications

Gastrointestinal Cancers | Tanios Bekaii-Saab, MD Sep 13, 2024

Show notes

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 2: Emerging Role of HER2-Targeted Therapy in Advanced Biliary Tract Cancers (BTCs) — Tanios Bekaii-Saab, MD

CME information and select publications

Non-Small Cell Lung Cancer with an EGFR Mutation | Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation Sep 12, 2024

Show notes

Featuring slide presentations and related discussion from Dr Pasi A Jänne, Prof Tom John, Dr Zofia Piotrowska and Dr Alexander I Spira, including the following topics:

Recent Advances in the Management of Localized and Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Prof John (0:00)
First-Line Treatment for Advanced NSCLC with an EGFR Mutation — Dr Spira (32:48)
Later-Line Therapy for Advanced NSCLC with an EGFR Mutation — Dr Jänne (1:03:51)
Management of NSCLC with an EGFR Exon 20 Mutation — Dr Piotrowska (1:33:33)

CME information and select publications

Dedifferentiated Liposarcoma | Oncology Today with Dr Neil Love: Optimizing the Management of Dedifferentiated Liposarcoma Sep 10, 2024

Show notes

Featuring perspectives from Dr Mrinal Gounder, including the following topics:

Epidemiology, classification, genetics and diagnosis of sarcomas (0:00)
Contemporary medical treatment of sarcomas (5:29)
Targeted therapy for the treatment of sarcomas (9:01)
Incidence, pathophysiology, classifications and clinical manifestations of liposarcomas (16:27)
Current clinical treatment of dedifferentiated liposarcomas (23:14)
Targeting the MDM2-p53 pathway for dedifferentiated liposarcomas (28:20)
Available data with MDM2 inhibitors for dedifferentiated liposarcomas (36:37)
Emerging research and future directions for dedifferentiated liposarcomas; clinical treatment landscape of desmoid tumors (1:01:22)

CME information and select publications